Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity

Annals of Oncology

Volumn 15, Issue 5, 2004, Pages 808-820

  Weirich, Angela ^a,e   Ludwig, R ^a   Graf, N ^b   Abel, U ^a   Leuschner, I ^c   Vujanic, G M ^d   Mehls, O ^e   Boos, J ^f   Beck, J ^g   Royer Pokora, B ^h   Voute P A ⁱ  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^g UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^h HEINRICH HEINE UNIVERSITY   (Germany)

ⁱ ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Late effects; Prognostic factors; Relapse; Survival; Wilm's tumor

Indexed keywords

CARBOPLATIN; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; MESNA; VINCRISTINE;

ANAPLASTIC CARCINOMA; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CHILD; CONTROLLED STUDY; DRASH SYNDROME; DRUG RESPONSE; EPITHELIUM TUMOR; FEMALE; FOLLOW UP; HEART DISEASE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; NEPHROBLASTOMA; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; STATISTICAL SIGNIFICANCE; STROMA CELL; TUMOR DIFFERENTIATION;

EID: 2642554099     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh171     Document Type: Article

References (41)

1. Lemmerle J, Voûte PA, Tournade MF et al. Effectiveness of pre-operative chemotherapy in Wilms' tumor: Results of an International Society of Pediatric Oncology (SIOP) clinical trial. J Clin Oncol 1983; 1: 604-609.
2. Tournade MF, Com-Nougue C, Voûte PA et al. Results of the Sixth International Society of Pediatric Oncology Wilms' tumor Trial and Study: a risk-adapted therapeutic approach in Wilms' tumor. J Clin Oncol 1993; 11: 1014-1023.
3. D'Angio GJ, Evans A, Beckwith JB et al. Treatment of Wilms' tumor. Results of the Third National Wilms' tumor study. Cancer 1989; 64: 349-360.
4. Tournade MF, Com-Nougue' C, de Kraker J et al. Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumor in children older than 6 months: results of the ninth International Society of Pediatric Oncology Wilms' Tumor Trial and Study. J Clin Oncol 2001; 19: 488-500.
5. Ludwig R, Weirich A, Poetter R et al. Preoperative chemotherapy of nephroblastoma. Preliminary results of the SIOP-9/GPO study. Klin Padiatr 1992; 204: 204-213.
6. Ludwig R, Weirich A, Bürger D et al. Application of a new therapeutic strategy for nephroblastoma in the area of the Society of Paediatric Oncology and Haematology SIOP 9/GPOH. Monatsschr Kinderheilkd 1997; 145: 128-135.
7. Weirich A, Leuschner I, Harms D et al. Clinical impact of histologic subtypes in localized non-anaplastic nephroblastoma treated according to the trial and study SIOP9/GPOH. Ann Oncol 2001; 12: 311-319.
8. Rieden K, Weirich A, Tröger J et al. Accuracy of diagnostic imaging before preoperative chemotherapy. Eur Radiol 1993; 3: 115-122.
9. Flentje M, Weirich A, Poetter R et al. Hepatotoxicity in irradiated nephroblastoma patients during postoperative treatment according to SIOP-9/GPOH. Radiother Oncol 1994; 31: 222-228.
10. Ludwig R, Weirich A, Abel U et al. Hepatotoxicity in patients treated according to the nephroblastoma trial and study SIOP-9/GPOH. Med Pediatr Oncol 1999; 33: 462-469.
11. de Kraker J, Lemerle J, Voûte PA et al. Wilms' tumor with pulmonary metastases at diagnosis: the significance of primary chemotherapy. J Clin Oncol 1990; 8: 1187-1190.
12. Pein F, Michon J, Valteau-Couanet D et al. High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms' tumor: a French Society of Pediatric Oncology study. J Clin Oncol 1998; 16: 3295-3301.
13. Hempel L, Kremens B, Weirich A et al. High dose consolidation with autologous stem cell rescue (ASCR) for nephroblastoma initially treated according to the SIOP9/GPOH trial and study. Klin Padiatr 1996; 4: 186-189.
14. Beckwith JB, Palmer NF. Histopathology and prognosis of Wilms' tumor. Results from the First National Wilms' Tumor Study. Cancer 1978; 41: 1937-1948.
15. Faria P, Beckwith JB, Mishra K et al. Focal versus diffuse anaplasia in Wilms' tumor: new definitions with prognostic significance. Am J Surg Pathol 1996; 20: 909-920.
16. Vujanic GM, Harms D, Sandstedt B et al. The new definitions of focal and diffuse anaplasia in Wilms tumour: The International Society of Paediatric Oncology experience. Med Pediatr Oncol 1999; 32: 317-323.
17. DCTD, NCI, NIH, DHHS. Cancer Therapy Evaluation Program. Common Toxicity Criteria Manual, Version 2.0. [On-line]. http://ctep.Cancer.gov/forms/CTCManual_v4_10-4-99.pdf (updated August 18, 1999).
18. Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trial requiring prolonged observation of each patient: II analysis and examples. Br J Cancer 1977; 35: 1-39.
19. Marabini E, Vaisecchi MG. Competing Risks. Analyzing Survival Data from Clinical Trials and Observational Studies. New York, NY: John Wiley 1995.
20. Fisher RA (ed.). Statistical Methods for Research Workers. Edinburgh, UK: Oliver & Boyd 1972.
21. Trotti D. The evolution and application of toxicity criteria. Semin Radiat Oncol 2002; 12: 1-3.
22. Paulino AC, Wen BC, Brown CK et al. Late effects in children treated with radiation therapy for Wilms' tumor. Int J Radiat Oncol Biol Phys 2000; 46: 1239-1246.
23. Hogeboom CH, Grosser SC, Guthrie KA et al. Stature loss following treatment for Wilms' tumor. Med Pediatr Oncol 2001; 36: 295-304.
24. Green DM, Peabody EM, Nan B et al. Pregnancy outcome after treatment for Wilms' tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol 2002; 20: 2506-2513.
25. Green DM, Breslow NE, Beckwith JB et al. Treatment with nephrectomy only for small, stage I/favorable histology Wilms' tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol 2001; 19: 3719-3724.
26. Pritchard-Jones K, Kelsey A, Vujanic G et al. Older age is an adverse prognostic factor in stage I, favorable histology Wilms' tumor treated with vincristine monotherapy: a study by the UKCCSG Wilms' tumor working group. J Clin Oncol 2003; 21: 3269-3275.
27. Breslow N, Olshan A, Beckwith JB et al. Epidemiology of Wilms' tumor. Med Pediatr Oncol 1993; 21: 172-181.
28. Bonadio JF, Storer B, Norkool P et al. Anaplastic Wilms' tumor: clinical and pathological studies. J Clin Oncol 1985; 3: 513-520.
29. Pritchard J, Imeson J, Barnes J et al. Results of the United Kingdom Children's Cancer Study Group First Wilms' Tumor Study. J Clin Oncol 1995; 13: 124-133.
30. Green DM, Breslow NE, Evans I et al. Treatment of children with stage IV favorable histology Wilms' tumor: a report from the National Wilms' Tumor Study Group. Med Pediatr Oncol 1996; 26: 147-152.
31. Green DM, Finklestein JZ, Tefft ME et al. Diffuse interstitial pneumonitis after pulmonary irradiation for metastatic Wilms' tumor. Cancer 1989; 63: 450-453.
32. Green DM, Grigoriev YA, Nan B et al. Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study group. J Clin Oncol 2001; 19: 1926-1934.
33. Kremer LC, van Dalen EC, Offringa M et al. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 2001; 19: 1-6.
34. Boccon-Gibod L, Rey A, Sandstedt B et al. Complete necrosis induced by preoperative chemotherapy in Wilms' tumor as an indicator of low risk. Med Pediatr Oncol 2000; 34: 183-190.
35. Ritchey ML, Green DM, Thomas PR et al. Renal failure in Wilms' tumor patients: a report from the National Wilms' Tumor Study Group. Med Pediatr Oncol 1996; 26: 75-80.
36. Shibata R, Takata A, Hashiguchi A et al, Responsiveness of chemotherapy based on the histological type and Wilms' tumor suppresor gene mutation in bilateral Wilms' tumor. Pathol Int 2003; 53: 214-220.
37. Coppes MJ, Arnold M, Beckwith JB et al. Factors affecting the risk of contralateral Wilms tumor development: a report from the National Wilms' Tumor Study Group. Cancer 1999; 85: 1616-1625.
38. Weirich A, Uhl M, Benninger CH et al. Neurologic complications in Wilms' tumor: Recurrence or neurotoxicity of vincristine. Med Pediatr Oncol 1995; 25: 314.
39. Gidding CEM, Kellie SJ, Kamps WA et al. Vincristine revisited. Crit Rev Oncol Hematol 1999; 29: 267-287.
40. Rossi R, Kleinebrand A, Godde A et al. Increased risk of ifosfamide-induced renal Fanconi's syndrome after unilateral nephrectomy. Lancet 1993; 341: 755.
41. Schumacher V, Schaerer K. Wuehl E et al: Spectrum of early onset nephrotic syndrome associated with WT1 missense mutations. Kidney Int 1998; 53: 1594-1600.